ASCO 2020：11项华北地区研究入选口头报告，17项Poster报告

受亚洲地区一新冠疫情受到影响，原定于5月末29日~6月末2日在费城举行的加拿大针灸学会（ASCO）年会月末份将首次以终点站上形式举办，这是目前最大规模的终点站上盛会。今天，大会的简述答案确认，共103个sessions，我国共有11项研究者入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡马替尼加卡培他丰主要用途HER2+心肌梗死乳腺肝癌（PHOEBE）：一项III期随机试验车。

三场：心肌梗死乳腺肝癌

笔记：我国医学科学院诊所徐兵河名誉教授、马飞名誉教授，北京大学附属诊所胡夕春名誉教授等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴持续性乳腺肝癌标准疗程后卡培他丰维持复音低剂量的III期试验车（SYSUCC-001）。

三场：乳腺肝癌—角化/区域/专用疗程

笔记：中都山大学公共卫生其中都心王树森名誉教授等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死脊髓的表型特征来得出结论脊髓脊液中都循环DNA测定的概率: 一新机器对抗来由对手

三场：一新机器解决来由问题

笔记：李美芹 李堪等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

人口为120人非尼对布基纳法索拉非尼作为后期肝细胞会肝癌的一终点站疗程：一项免费首页、随机、多其中都心II/III期试验车。

三场：中都枢神经肝癌—胃气管、坏死和实乃

笔记：西安交通大学华西诊所毕锋名誉教授、我国人民解放军八一诊所秦叔逵名誉教授等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

我国后期肝肝癌病变阿帕替尼二终点站疗程：一项随机、疗效折衷、CPAIII期研究者

三场：中都枢神经肝癌—胃气管、坏死和实乃

笔记：我国人民解放军八一诊所秦叔逵名誉教授、西安交通大学华西诊所李秋名誉教授等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期病症脊髓瘤二次细胞会减灭术的一项随机III期试验车：SOC1 / SGOG-OV2。

专刊：诊疗前列腺癌

笔记：北京大学附属中都山诊所臧荣余名誉教授等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肝癌根治持续性子宫切除术后专用疗程中都的序贯放低剂量对比单独超声或同步放低剂量（STARS研究者）：一项随机、折衷、免费首页的III期试验车。

大会：诊疗前列腺癌

笔记：中都山大学公共卫生其中都心黄鹤名誉教授、刘继红名誉教授等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专用吉非替尼对比低剂量主要用途可切除的EGFR持续性状的N1-N2期NSCLC-随机III期的测试的最终总体求生存统计分析。

专刊：膀胱肝癌—非小细胞会角化-区域/小细胞会/其他胸部

笔记：中山市人民诊所吴一龙名誉教授等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR持续性状俱转移非小细胞会膀胱肝癌病变一终点站嘧啶激酶抑制剂重一新组建或不重一新组建努力前终点站角化超声：III期免费首页针灸随机试验车（SINDAS）的中都期结果（NCT02893332）。

专刊：膀胱肝癌-非小细胞会转移

笔记：四川省人民诊所曾铭名誉教授等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对一般而言失踪-1（PD-1）的人源化IgG4单克隆抗体重一新组建阿昔替尼主要用途心肌梗死黏膜卵巢癌病变的Ib期研究者的总求生存期和生物标志物统计分析。

专刊：卵巢癌/皮肤肝癌

笔记：清华大学诊所郭军、盛锡楠名誉教授等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全持续性和结果：区别于CAR-T细胞会首次人体试验车疗程中风/难治持续性T细胞会急持续性淋巴细胞会前列腺癌（r/r T-ALL）的安全持续性和。大会：开发中都的疗程关键技术-免疫疗程。笔记：王欣欣等简述：3013的广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后期气管鳞状细胞会肝癌病变中都的广泛应用：一项随机的免费首页II期试验车（ORIENT-2）。大会：中都枢神经肝癌-胃气管肝癌、坏死肝癌和实乃道肝癌笔记：徐建明名誉教授等简述：4511的广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异持续性CAR-T细胞会对髓母细胞会瘤的根除持续性疗程大会：血清素笔记：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、李旭东简述：2522的广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复缺陷病变中都的广泛应用大会：开发中都的疗程学-免疫疗程笔记：沈琳名誉教授等简述：3021的广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程中风/难治持续性ACUTE淋巴细胞会前列腺癌/失智症的月末所人体的测试大会: 开发持续性疗程学-免疫疗程笔记简介：张明志，南部县等简述：3026的广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重一新组建应主要用途后期实体瘤病变的Ib期研究者大会：发展持续性疗程学；还有分子抑制剂药物和微生物学笔记：龚继芳，沈琳名誉教授等简述：3523的广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重一新组建紫杉醇和nedaplatin疗程病症或心肌梗死气管鳞状细胞会肝癌（ESCC）病变的II期研究者。大会：中都枢神经肝癌-胃气管、坏死和实乃道肝癌的研究者笔记：王志最弱，李玉红，王德申，王凤华，任超，谭琼 王志最弱、李玉红、王德深、王凤华、任超、谭琼简述：4522的广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：中都枢神经肝癌-胃气管肝癌、坏死肝癌和实乃管肝癌的二终点站疗程笔记：宋艳等简述：4524的广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体内环RNA分类器主要用途初始前列腺时测定高等级肝癌的尿液外体内环RNA分类器：一项多其中都心的回顾持续性研究者大会：泌尿生殖系统前列腺癌；还有-肝癌、睾丸肝癌和肝癌笔记简介：Liaoyuan Li等简述：5522的广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 角化后期宫颈肝癌并发低剂量后的专用低剂量大会: 诊疗前列腺癌笔记简介： 李珉珉等简述：6031的广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺髓持续性肝癌的连续持续性：基于ALTER01031试验车的统计分析。会话：头颈部笔记：天津市诊所正派名誉教授简述：6526的广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年岁对安洛替尼疗程后病变故事情节的受到影响: ALTER01031的亚组统计分析大会：头颈部笔记：天津市诊所正派名誉教授简述：6527的广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析得出结论I-IIIA期非小细胞会膀胱肝癌（NSCLC）病变术后中风: GASTO1035和GASTO1018的结果大会：膀胱肝癌-非小细胞会角化-区域持续性/小细胞会/小细胞会/其他胸科前列腺癌笔记：Si-Yu Wang等简述：9023的广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会膀胱肝癌（NSCLC）中都EGFR嘧啶激酶抑制剂的一新型致病机制大会:膀胱肝癌-非小细胞会心肌梗死膀胱肝癌笔记简介：李昕，金结缘，满宇，欧秋香，才与，薛武，杨少，范敏 李昕、金结缘、满宇、欧秋香、才与、薛武、杨绍、范敏简述：9528的广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验车中都后期卵巢癌总求生存的替代终点大会：卵巢癌/皮肤肝癌笔记：聂润聪，袁书最弱，李元芳，陈英波，周志伟 聂润聪、袁书最弱、李元芳、陈英波、周志伟简述：10030的广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程中风或心肌梗死原发持续性恶持续性骨病变的II期研究者大会： 肉瘤笔记：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、曹吉祥、蔡启庆、涂崇奇、范正福、杨瑶简述：11525的广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后期肉瘤病变多终点站疗程中都的安全持续性和。大会：肉瘤笔记：姚伟涛，王家最弱，张鹏，王欣，杜一新辉，田志浩，牛晓颖 姚伟涛、王家最弱、张鹏、王鑫、杜鑫辉、田志超、牛晓英简述：11526的广告：414